17/10/2022 (Agence Europe) – On 13 October, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the authorisation of the live inactivated tetravalent vaccine developed by the Japanese pharmaceutical company Takeda Pharmaceutical to prevent the disease caused by serotypes 1, 2, 3 and 4 of the dengue virus. The vaccine can be given from the age of 4 years. The EMA states that, for the first time, the CHMP is examining a medicinal product simultaneously for the European market, through the centralised procedure, and for marketing in third countries via ‘European Medicines for All’, a procedure developed with the World Health Organization and based on Article 58 of EC Regulation No. 726/2004, which allows for the accelerated authorisation of high-priority human medicinal products intended for third-country markets. (EV)